home / stock / cocp / cocp quote
Last: | $2.38 |
---|---|
Change Percent: | 0.43% |
Open: | $2.29 |
Close: | $2.38 |
High: | $2.4952 |
Low: | $2.29 |
Volume: | 62,705 |
Last Trade Date Time: | 07/05/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$2.38 | $2.29 | $2.38 | $2.4952 | $2.29 | 62,705 | 07-05-2024 |
$2.3 | $2.395 | $2.3 | $2.471 | $2.3 | 1,503 | 07-04-2024 |
$2.3 | $2.395 | $2.3 | $2.471 | $2.3 | 1,503 | 07-03-2024 |
$2.36 | $2.34 | $2.36 | $2.6 | $2.34 | 31,854 | 07-02-2024 |
$2.4 | $2.29 | $2.4 | $2.41 | $2.29 | 8,109 | 07-01-2024 |
$2.33 | $2.55 | $2.33 | $2.55 | $2.28 | 18,821 | 06-28-2024 |
$2.55 | $2.45 | $2.55 | $2.6 | $2.43 | 4,583 | 06-27-2024 |
$2.44 | $2.44 | $2.44 | $2.465 | $2.43 | 7,287 | 06-26-2024 |
$2.45 | $2.58 | $2.45 | $2.64 | $2.45 | 4,566 | 06-25-2024 |
$2.61 | $2.69 | $2.61 | $2.7804 | $2.46 | 35,405 | 06-24-2024 |
$2.66 | $2.58 | $2.66 | $2.66 | $2.43 | 23,290 | 06-21-2024 |
$2.55 | $2.4 | $2.55 | $2.78 | $2.4 | 36,451 | 06-20-2024 |
$2.49 | $2.4 | $2.49 | $2.6 | $2.4 | 29,297 | 06-19-2024 |
$2.49 | $2.4 | $2.49 | $2.6 | $2.4 | 29,297 | 06-18-2024 |
$2.4061 | $2.33 | $2.4061 | $2.51 | $2.31 | 13,513 | 06-17-2024 |
$2.39 | $2.65 | $2.39 | $2.65 | $2.3 | 53,885 | 06-14-2024 |
$2.6101 | $2.76 | $2.6101 | $2.9893 | $2.53 | 64,350 | 06-13-2024 |
$2.8 | $2.75 | $2.8 | $3.1 | $2.7 | 96,658 | 06-12-2024 |
$2.72 | $2.47 | $2.72 | $2.72 | $2.47 | 24,308 | 06-11-2024 |
$2.53 | $2.53 | $2.53 | $2.5981 | $2.45 | 20,126 | 06-10-2024 |
News, Short Squeeze, Breakout and More Instantly...
Cocrystal Pharma Inc. Company Name:
COCP Stock Symbol:
NASDAQ Market:
Cocrystal Pharma Inc. Website:
BOTHELL, Wash., June 20, 2024 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc .’s (Nasdaq: COCP) novel, broad-spectrum antiviral CC-42344 inhibits activity in the highly pathogenic avian influenza A (H5N1) PB2 protein recently identified in infected dairy cattle, according to recently ...
Topline single ascending dose (SAD) Phase 1 results of oral CDI-988, the first potential pan-coronavirus-pan-norovirus oral antiviral, expected in the second quarter of 2024 Enrollment completed in Phase 2a influenza A human challenge study of oral CC-42344, with topline results expected ...
BOTHELL, Wash., May 01, 2024 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces completion of enrollment of 78 subjects who were infected with influenza A in a randomized, double-blind, placebo-controlled Phase 2a human...